BeOne Medicines Ltd.
BEIGFDrugs in Pipeline
17
Phase 3 Programs
8
Upcoming Catalysts
9
Next Catalyst
This month
Market Overview
Stock performance and key metrics
9 upcoming, 1 past
Sonrotoclax Phase 2 Est. Readout
Estimated primary completion for Sonrotoclax trial (NCT05952037) in Waldenstrom Macroglobulinemia. Topline data typically follows completion by weeks to months.
SourceOxaliplatin Phase 3 Est. Readout
Estimated primary completion for Oxaliplatin trial (NCT05152147) in Gastric Neoplasms. Topline data typically follows completion by weeks to months.
Source7 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How BEIGF's past catalysts played out
Sonrotoclax
Waldenstrom Macroglobulinemia
Zanubrutinib
Chronic Lymphocytic Leukemia
bendamustine
Mantle Cell Lymphoma; Non-Hodgkin Lymphoma
Tislelizumab
Colorectal Cancer
Tacrolimus
Primary Membranous Nephropathy
Oxaliplatin
Advanced Unresectable Gastric Adenocarcinoma
Tacabrutideg
Chronic Lymphocytic Leukemia
BGB-16673
B-cell Malignancy
PD-1/PD-L1 inhibitors
Borderline Resectable Carcinoma
BGB-B2033
Metastatic Hepatocellular Carcinoma
ZW25 (Zanidatamab)
HER2-amplified Biliary Tract Cancers
CAR-T Cell Therapy
Mantle Cell Lymphoma
Blinatumomab
Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
Fludarabine
Recurrent Transformed Chronic Lymphocytic Leukemia
BGB-11417
Acute Myeloid Leukemia
Dexamethasone
Relapsed/Refractory Multiple Myeloma
Leucovorin
Gastroesophageal Adenocarcinoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Sonrotoclax | Phase 3 | Waldenstrom Macroglobulinemia | - | - |
Zanubrutinib | Phase 3 | Chronic Lymphocytic Leukemia | - | - |
bendamustine | Phase 3 | Mantle Cell Lymphoma; Non-Hodgkin Lymphoma | - | - |
Tislelizumab | Phase 3 | Colorectal Cancer | - | - |
Tacrolimus | Phase 3 | Primary Membranous Nephropathy | - | - |
Oxaliplatin | Phase 3 | Advanced Unresectable Gastric Adenocarcinoma | - | - |
Tacabrutideg | Phase 3 | Chronic Lymphocytic Leukemia | - | - |
BGB-16673 | Phase 3 | B-cell Malignancy | - | - |
PD-1/PD-L1 inhibitors | Phase 2 | Borderline Resectable Carcinoma | - | - |
BGB-B2033 | Phase 2 | Metastatic Hepatocellular Carcinoma | - | - |
ZW25 (Zanidatamab) | Phase 2 | HER2-amplified Biliary Tract Cancers | - | - |
CAR-T Cell Therapy | Phase 2 | Mantle Cell Lymphoma | - | - |
Blinatumomab | Phase 2 | Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia | - | - |
Fludarabine | Phase 2 | Recurrent Transformed Chronic Lymphocytic Leukemia | - | - |
BGB-11417 | Phase 2 | Acute Myeloid Leukemia | - | - |
Dexamethasone | Phase 2 | Relapsed/Refractory Multiple Myeloma | - | - |
Leucovorin | Phase 2 | Gastroesophageal Adenocarcinoma | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in BeOne Medicines Ltd.'s drug pipeline?→
CatalystAlert tracks 17 drug candidates in BeOne Medicines Ltd.'s (BEIGF) pipeline across Phase 3, Phase 2. Its lead program is Sonrotoclax (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is BeOne Medicines Ltd.'s next FDA catalyst?→
BeOne Medicines Ltd.'s (BEIGF) next tracked catalyst is a Phase 2 expected September 22, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track BEIGF biotech catalysts?→
Add BEIGF to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow BeOne Medicines Ltd.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.